^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    everolimus

    i
    Other names: RAD, RAD001, SDZ RAD, RAD 001
    Associations

    News

    Trials
    Company:
    Generic mfg.
    Drug class:
    mTOR inhibitor
    Related drugs:
    Associations

    News

    Trials
    4years
    PerELISA: Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients (clinicaltrials.gov)
    P1, N=37, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Jul 2021 --> Dec 2020 | Trial primary completion date: Jul 2021 --> Dec 2020
    Clinical • Trial completion • Trial completion date • Trial primary completion date
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 amplification • HER-2 mutation
    |
    everolimus • letrozole
    over4years
    Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors (clinicaltrials.gov)
    P1, N=22, Completed, Pediatric Brain Tumor Consortium | Recruiting --> Completed | N=45 --> 22 | Trial completion date: Jul 2020 --> Apr 2020 | Trial primary completion date: Jul 2020 --> Apr 2020
    Clinical • Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    RB1 (RB Transcriptional Corepressor 1)
    |
    everolimus • Kisqali (ribociclib)
    over4years
    Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (clinicaltrials.gov)
    P2, N=20, Completed, Mayo Clinic | Active, not recruiting --> Completed
    Clinical • Trial completion
    |
    ER (Estrogen receptor) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    ER positive • MUC16 elevation
    |
    everolimus • letrozole
    almost5years
    S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer (clinicaltrials.gov)
    P3, N=37, Terminated, Southwest Oncology Group | N=825 --> 37 | Trial completion date: May 2022 --> Dec 2019 | Suspended --> Terminated | Trial primary completion date: May 2022 --> Dec 2019; lack of accrual
    Clinical • Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)
    |
    HER-2 amplification
    |
    everolimus • fulvestrant • anastrozole
    almost5years
    A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005) (clinicaltrials.gov)
    P3, N=736, Recruiting, Merck Sharp & Dohme Corp. | Not yet recruiting --> Recruiting
    Clinical • Enrollment open
    |
    PD-L1 (Programmed death ligand 1)
    |
    everolimus • Welireg (belzutifan)
    5years
    Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative (clinicaltrials.gov)
    P2, N=37, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2021 --> Jan 2022 | Trial primary completion date: Jan 2020 --> Jan 2021
    Clinical • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • VIM (Vimentin)
    |
    Avastin (bevacizumab) • everolimus • pegylated liposomal doxorubicin • doxorubicin liposomal